Next-generation sequencing (NGS) technology offers new opportunities to discover additional mutational profiles in the AML genome, such as the genes encoding DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 1 and 2 (IDH1/2), and Tet oncogene family member 2 (TET2) [8], which are key to DNA methylation modification and are involved in the pathogenesis of leukemia [9, 10]. This evidence concerns the gene IDH1 and acute myeloid leukemia.